Inhibiting MAPK14 showed anti-prolactinoma effect
Abstract Background The specific underlying pathogenesis of prolactinoma has not been clarified yet, to the best of our knowledge. p38 mitogen-activated protein kinase (MAPK) signaling including p38α MAPK (MAPK14), p38β (MAPK11), p38γ (MAPK12) and p38δ (MAPK13) is associated with the development and...
Main Authors: | Qiao-yan Ding, Yu Zhang, Li Ma, Yong-gang Chen, Jin-hu Wu, Hong-feng Zhang, Xiong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | BMC Endocrine Disorders |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12902-020-00619-z |
Similar Items
-
Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications
by: Betina Biagetti, et al.
Published: (2021-10-01) -
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
by: Shuman Wang, et al.
Published: (2021-11-01) -
Interpretation of the 2022 ICCE/AME Position Statement for Clinical Practice in Pituitary Prolactinoma: Update on Clinical Characteristics and Points of Diagnosis and Treatment of Pituitary Prolactinoma
by: TAN Huiwen, LI Danting, YU Yerong
Published: (2024-02-01) -
Mean platelet volume in patients with prolactinoma
by: Abbas Ali Tam, et al.
Published: (2016-02-01) -
Current and Perspective Approaches to the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2023-07-01)